Aquestive Therapeutics (AQST) Free Cash Flow (2017 - 2025)
Historic Free Cash Flow for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$12.9 million.
- Aquestive Therapeutics' Free Cash Flow fell 772.58% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.9 million, marking a year-over-year decrease of 4821.37%. This contributed to the annual value of -$35.9 million for FY2024, which is 38702.37% down from last year.
- Per Aquestive Therapeutics' latest filing, its Free Cash Flow stood at -$12.9 million for Q3 2025, which was down 772.58% from -$8.0 million recorded in Q2 2025.
- Aquestive Therapeutics' 5-year Free Cash Flow high stood at $8.8 million for Q1 2023, and its period low was -$23.5 million during Q1 2025.
- For the 5-year period, Aquestive Therapeutics' Free Cash Flow averaged around -$7.0 million, with its median value being -$8.0 million (2025).
- Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 19762.63% in 2022, then plummeted by 37878.3% in 2024.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Free Cash Flow stood at -$8.6 million in 2021, then skyrocketed by 197.63% to $8.4 million in 2022, then crashed by 159.09% to -$5.0 million in 2023, then crashed by 31.18% to -$6.5 million in 2024, then tumbled by 98.09% to -$12.9 million in 2025.
- Its Free Cash Flow stands at -$12.9 million for Q3 2025, versus -$8.0 million for Q2 2025 and -$23.5 million for Q1 2025.